XML 29 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Data (Tables)
 9 Months Ended
Sep. 27, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Reportable Segment
Selected information by reportable segment was as follows:

Three Months Ended
 
Nine Months Ended

September 27,
2019
 
September 28,
2018
 
September 27,
2019
 
September 28,
2018
Net sales:
 
 
 
 
 
 
 
Specialty Brands
$
580.4

 
$
640.0

 
$
1,812.4

 
$
1,844.3

Specialty Generics
163.3

 
159.9

 
545.2

 
536.4

Net sales
$
743.7

 
$
799.9

 
$
2,357.6

 
$
2,380.7

Operating income (loss):
 
 
 
 
 
 
 
Specialty Brands
$
267.3

 
$
288.0

 
$
864.2

 
$
794.4

Specialty Generics
21.8

 
16.5

 
80.1

 
94.7

Segment operating income
289.1

 
304.5

 
944.3

 
889.1

Unallocated amounts:
 
 
 
 
 
 
 
Corporate and unallocated expenses (1)          
(23.4
)
 
(29.2
)
 
(105.6
)
 
(85.7
)
Intangible asset amortization
(210.4
)
 
(184.2
)
 
(649.8
)
 
(546.5
)
Restructuring and related charges, net
(7.2
)
 
(19.6
)
 
(11.2
)
 
(106.6
)
Non-restructuring impairment charges
—

 
(2.0
)
 
(113.5
)
 
(2.0
)
Separation costs (2)
(19.8
)
 
—

 
(50.4
)
 
—

R&D upfront payment (3)
(20.0
)
 
—

 
(20.0
)
 
—

Operating income (loss) (4)
$
8.3

 
$
69.5

 
$
(6.2
)
 
$
148.3



(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
(2)
Represents costs incurred related to the separation of the Company's Specialty Generics segment, inclusive of costs related to the suspended spin-off of that business and rebranding costs associated with the Specialty Brands ongoing transformation, all of which are included in SG&A.
(3)
Represents R&D expense incurred related to an upfront payment made to Silence in connection with the license and collaboration agreement entered into in July 2019. Refer to Note 15 for further details.
(4)
The amount of operating loss included in the Company's unaudited condensed consolidated statement of income for the three and nine months ended September 28, 2018 related to the Sucampo Acquisition was $32.2 million and $99.9 million, respectively. Included within these results were $18.0 million and $45.0 million of amortization associated with intangibles recognized from this acquisition and $31.0 million and $77.5 million of expense associated with fair value adjustments of acquired inventory for the three and nine months ended September 28, 2018, respectively.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's reportable segments were as follows:
 
Three Months Ended
 
Nine Months Ended
 
September 27,
2019
 
September 28,
2018
 
September 27,
2019
 
September 28,
2018
Acthar Gel
$
229.8

 
$
290.1

 
$
720.1

 
$
827.1

Inomax
136.8

 
133.2

 
427.6

 
404.0

Ofirmev
86.1

 
87.1

 
272.2

 
254.7

Therakos
60.9

 
60.0

 
183.6

 
174.2

Amitiza (1)
52.6

 
48.2

 
157.6

 
119.2

BioVectra
10.5

 
13.9

 
36.8

 
35.7

Other
3.7

 
7.5

 
14.5

 
29.4

Specialty Brands
580.4

 
640.0

 
1,812.4

 
1,844.3

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
15.7

 
15.5

 
51.2

 
46.3

Oxycodone (API) and oxycodone-containing tablets
17.2

 
13.6

 
53.3

 
43.3

Acetaminophen (API)
48.5

 
47.9

 
143.1

 
149.0

Other controlled substances
72.9

 
69.5

 
265.7

 
258.0

Other
9.0

 
13.4

 
31.9

 
39.8

Specialty Generics
163.3

 
159.9

 
545.2

 
536.4

Net sales
$
743.7

 
$
799.9

 
$
2,357.6

 
$
2,380.7


(1)
Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.